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Abstract: Due to the COVID-19 infection, which was recognized as a global pandemic by the WHO on March 11, 2020, the
number of cases and disease-related deaths increases day by day globally. For this reason, antiviral agents used in treatment
and vaccines, the most effective weapon in prevention, continue to be the most popular topic of the plan. Several situations
are expected to affect the course of the pandemic. The loss of the ability of the virus to mutate and cause disease, the fact that
those who become immunized by having the disease in the society reach a critical rate and create social immunity (herd
immunity), and the provision of social immunity with effective vaccination can be counted as some of these situations.
Candidate vaccines in the clinical phase among RNA-based vaccines: This review aimed to examine COVID-19 vaccine
candidates using RNA technology and compile its current data. We used PubMed, Google Scholar, and World Health
Organization (WHO) databases. Also, we followed up on the latest news and developments on vaccine companies’ websites.
Conclusion: Vaccination trials, which started due to the seriousness and urgency of the situation that we are in, continue exceptionally
quickly and effectively. As per the WHO›s data on July 9, 2021, there have been 291 vaccine trials, 107 of which are in the clinical phase,
and 18 (16%) of the vaccine candidates in the clinical phase are RNA-based vaccines. Also, the number of RNA-based vaccines with
ongoing preclinical trials is 2
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1. Introduction
With the investigation of pneumonia cases, which first
appeared in Wuhan, China, in December 2019, seen in
different cities outside Wuhan in January 2020, the actual
cause could not be fully revealed. It was revealed that the
factor was a new type of coronavirus on January 7, 2020
[1]. This virus has been named 2019-nCoV (2019-novel
coronavirus) by the World Health Organization (WHO)
and as SARS-CoV-2 (severe acute respiratory syndrome
coronavirus-2) by the International Virus Taxonomy
Committee.1 Also, the disease caused by the virus is
named COVID-19 (coronavirus disease-2019). The
disease typically progresses with respiratory system
symptoms, but it can also progress multisystemic due to
the endothelial damage it causes. Cardiovascular and
1

central nervous system involvement, bleeding diathesis,
and ocular findings are frequently observed [2–6].
WHO declared COVID-19 as a global pandemic on
March 11, 2020.2 According to WHO data, the total number
of confirmed COVID-19 cases worldwide as of July 9, 2021
is 185,291,530, and the total number of reported deaths
due to disease has reached 4,010,834. The first COVID-19
case in Turkey was seen on March 10, 2020, and the first
death reported due to this disease was on April 11, 2020.
When countries worldwide are ranked according to
the total number of COVID-19 cases, the United States
of America (USA) comes first, followed by the IndiaBrazil-Russia-France. Our country is in fifth place in this
ranking with a total number of 5,465,094 cases.3 As in our
country, the number of people infected with COVID-19
and deaths due to disease increases day by day.4 Because

International Committee on Taxonomy of Viruses (2021) [online] Website https://talk. ictvonline.org [accessed 20 January 2021].

World Health Organization (2020) [online] Website https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarksat-the-media-briefing-on-covid-19 [accessed 11 March 2020].
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World Health Organization Coronavirus Disease (COVID-19) Dashboard (2021) [online] Website https://covid19.who.int/ [accessed 20 April 2021].

Republic of Turkey Ministry of Health General Directorate of Public Health (2021) [online] Website https://hsgm.saglik.gov.tr/tr/covid19 [accessed 11
March 2021].
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of this situation, both vaccines and antiviral agents used
in treatment gain more importance, and accordingly, they
occupy the agenda intensely.
As with many infectious diseases, vaccines are critical
in preventing COVID-19 infection. According to the
WHO’s data, on July 9, 2021, the number of COVID-19
vaccine trials worldwide is 291 in total; 107 of them are
in the clinical phase, while 184 are in the preclinical stage.
Among the RNA-based vaccines subject to our review, the
number of vaccines in the clinical phase is 18, while the
number in the preclinical phase is 24.5
The distribution of 107 vaccine candidates, of which
clinical trials are in progress, as per the technologies they
use, is shown in Table 1.
New vaccine development trials are performed in 4
phases, just like the development of new drugs. In Phase
I, vaccines are generally administered to a volunteer
population of 50–100 people to determine the safety and
effective dose. Vaccines found to be effective and safe in
phase I are tested within Phase II trials in larger numbers
of healthy volunteers of different ages and sometimes
with underlying diseases (usually placebo-controlled). In
a classic Phase II trial, the number of volunteers ranges
from 400–1000. At this stage, vaccines, which are effective
and reliable, are used in Phase III with placebo control
in volunteer populations with varying ages and health/
underlying disease characteristics, expressed in tens of
thousands. Vaccines that are found to be effective and safe
due to this phase trials apply to the relevant authorities for
authorization approval.6
The trials conducted after the vaccine is authorized
(postmarketing) are called Phase IV trials. Most phase
trials were conducted in combination as Phase I and II/
Phase II and III during the COVID-19 pandemic.
In recent years, m-RNA technology has been used in
RNA-based vaccines, which have developed rapidly. Many
preclinical trials have been found, and the number of
clinical trials has increased significantly in the last few years.
m RNA is the intermediate step between the translation of
protein-encoding DNA and the production of proteins by
ribosomes in the cytoplasm. The proteins are transmitted
to the ribosomes in the cytoplasm by mRNA transcription,
and, thus, the relevant protein synthesis is provided. Naked
m-RNA is degraded by extracellular RNases and, therefore,
cannot be effectively uptake into the cell. Naked m-RNA is
degraded by extracellular RNases and, therefore, cannot be
effectively uptake into the cell. This condition disrupts the
stability and effectiveness of m-RNA-based vaccines. For
this reason, the half-life of mRNAs is extended by ensuring

the stability of the 3’ and 5’ UTR regulatory sequences
obtained from the viral or eukaryotic genes used. Besides,
mRNA stability and protein translation can be achieved by
adding the appropriate length of poly-(A)-tail [7]. Various
mRNA vaccine platforms have been developed in recent
years and validated in studies of immunogenicity and
efficacy. Engineering of the RNA sequence has rendered
synthetic mRNA more translatable than ever before. Highly
efficient and nontoxic RNA carriers have been developed
in a way that, in some cases, allows prolonged antigen
expression in vivo. Some vaccine formulations contain
novel adjuvants, while others elicit potent responses in
the absence of known adjuvants. Two major types of RNA
are currently studied as vaccines: nonreplicating mRNA
and virally derived, self-amplifying RNA. Conventional
mRNA-based vaccines encode the antigen of interest and
contain 5′ and 3′ untranslated regions (UTRs). In contrast,
self-amplifying RNAs encode the antigen and the viral
replication machinery that enables intracellular RNA
amplification and abundant protein expression.
These vaccines are safe vaccines that do not have an
infectious potential, and they cause a potent immune
response by stimulating both innate immunity and
adaptive immunity with protein translation. Besides, they
are stable vaccines with fast-cheap-scalable production
potential. RNA-based vaccines generally have to be stored
at very low temperatures. This situation emerges as a
logistical problem that may be encountered during the
vaccination of large human populations. Also, allergic
events and autoimmune diseases can be triggered by the
potent immune response they cause.
RNA-based vaccine candidates, of which phase III
trials are ongoing, use m-RNA technology encodes the
COVID-19 spike protein. Phase III trials have been
completed, and the first results are announced in four
m-RNA-based
vaccines
(Pfizer/Biontech-Moderna,
CureVac, Academy of Military Science (AMS)-Walvax
Biotechnology). Also, two m RNA-based vaccines recently
reported the results of Phase IV trials (Pfizer/Biontech and
Moderna). Candidate vaccines in the clinical phase among
RNA-based vaccines are categorized in Table 2.
2.1. Pfizer-Biontech
On the basis of initial clinical-trial results in Germany, two
lipids nanoparticle–formulated, nucleoside-modified
RNA (modRNA) vaccine candidates against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) were
evaluated in the Phase I portion of the trial in the United
States. One of these candidates, BNT162b1, encodes the
SARS-CoV-2 receptor–binding domain, trimerized by the

World Health Organization The DRAFT Landscape of COVID-19 Candidate Vaccines (2021) [online] Website https://www.who.int/publications/m/
item/draft-landscape-of-covid-19-candidate-vaccines [accessed 11 March 2021].
5

Centers for Disease Control and Prevention Vaccine testing and the approval process (2021) [online] Website https://www.cdc.gov/vaccines/basics/
test-approve.html [accessed 11 March 2020].
6
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Table 2. Candidate vaccines in the clinical phase among RNA-based vaccines.
Pfizer-Biontech
Moderna
CureVac
Arcturus Therapeutics
Imperial College London
Academy of Military Science (AMS)- Walvax Biotechnology
Providence Therapeutics
Chulalongkorn University
GlaxoSmithKline
Moderna + National Institute of Allergy and Infectious Diseases (NIAID)
Sanofi Pasteur and Translate Bio.
Daiichi Sankyo Co., Ltd.
ModernaTX, Inc. (m RNA 1273.211 Multivalent Booster )
MRC/UVRI and LSHTM Uganda Research Unit
Shanghai East Hospital
Elixirgen Therapeutics
Senai Cimatec
ModernaTX (m RNA 1283)
Table 1. RNA-based COVID-19 vaccine candidates with used technologies.
Platform

Used technologies

Candidate vaccines (n) (%)

PS

Protein subunit

36 (34%)

VVnr

Viral vector (nonreplicating)

15 (14%)

DNA

DNA

10 (9%)

IV

Inactivated virus

16 (15%)

RNA

RNA

18 (17%)

VVr

Viral vector (replicating)

2 (2%)

VLP

Virus-like particle

5 (5%)

VVr + APC

VVr + Antigen presenting cell

2 (2%)

LAV

Live attenuated virus

2 (2%)

VVnr + APC

VVnr + Antigen presenting cell

1 (1%)

Total

addition of a T4 fibritin fold on the domain to increase its
immunogenicity through the multivalent display. The other
candidate, BNT162b2, encodes the SARS-CoV-2 full-length
spike, modified by two proline mutations to lock it in the
prefusion conformation and more closely mimic the intact
virus with which the elicited virus-neutralizing antibodies
must interact. Because of the higher reactogenicity of
BNT162b1 in older people, BNT162b2 was used in the
Phase III trial: the safety, tolerability, and immunogenicity
data of Phase I and Phase II trials conducted in Germany.
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107 (100%)

Also, the data were published in October 2020. Accordingly,
60 volunteers were vaccinated with the Pfizer-Biontech
vaccine (BNT162b1) between April 23, 2020, and May 22,
2020. The trial was designed with 12 participants in each
dose group. Double dose vaccination was made to 1 μg-10
μg-30 μg-, and 50 μg-groups on 1st and 22nd days and single
dose to 60 μg-group. Participants consisted of healthy males
between the ages of 20–56 and healthy females who were
not pregnant, and the median age was 37 years. A total of
96.7% of the participants were Caucasian, 1 participant was
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African American, and 1 participant was Asian. No severe
adverse events were observed in any of the participants (at
any dose) followed after vaccination. Systemic side effects
reported in the 10 μg to 30 μg groups typically occurred
within 24 h following the first injection and are dependent
on reactogenicity as expected. Pain and tenderness at the
injection site were the most common reactions in the seven
days following the 1st and 2nd dose and were reported as
dose-dependent and were more common after the 2nd
dose. Symptoms such as fever, headache, joint pain, muscle
pain, pain, and tenderness at the injection site were often
mild/moderate and rarely more severe. However, even
severe symptoms are transient and resolved spontaneously
or controlled with simple interventions (e.g., paracetamol).
Transient CRP elevation and transient decrease in
lymphocyte count have been reported after vaccination,
both being dose-dependent. The increase in CRP level has
been explained as an indicator of the vaccine’s adjuvant
molecule activity. Transient decrease in lymphocyte count
is related to the redistribution of lymphocytes to lymphoid
organs due to stimulation of the innate immune system.
Both cases are pharmacodynamic markers that show the
activity of RNA vaccines.
In the trial, baseline RBD-binding Ig G and SARSCoV-2 neutralizing Ab levels of the participants were
examined; control antibody levels were examined 7
and 21 days (days 8–22 and days 29–43) after the 1st
and 2nd doses in the other groups, except for the 60 μg
group, which was administered as a single dose. Strong
vaccine-induced antibody response was reported in a
dose-dependent manner in all vaccinated participants.
The geometric mean concentration of RBDbinding Ig G
(geometric mean concentration/GMC) measured 21 days
after the 1st injection in the four dose groups increased
dose-dependently (265–1672 unit (U) ml−1). The RBDbinding IgG level in antibody titers measured seven days
(29th day) and 21 days (43rd day) after the 2nd dose
increased strongly depending on the dose (29. Day GMC:
2015–25.006 U mL−1.) (43. Day GMC: 3.920–18.289 U
mL−1 I).
After the single dose of 60 μg vaccination, the antibody
GMC value measured on the 43rd day was reported as 755
U ml−1, and it was stated that a 2nd dose was required to
increase the antibody level.
The SARS-CoV-2 neutralizing antibody geometric
mean titer (GMT) measured on the 22nd day following the
1st dose of vaccination was found to be dose-dependent
increased. The neutralizing antibody GMT values
measured seven days after the second dose were 36 in the
1 μg group, 158 in the 10 μg group, 308 in the 30 μg group,
and 578 in the 50 μg group, respectively. Neutralizing
antibody GMT value and RBD-binding Ig G GMC titers
were found to be decreased 21 days after the 2nd dose of

vaccine (43rd day). (Except for 1 μg dose group) Serum
virus-neutralizing antibody titer is strongly correlated
with RBD-binding IgG titer.
BNT162b1 results gave similar results with the trial
conducted in the USA.
CD4 (+) and CD8 (+) T cell responses were examined
using the ex vivo IFNγ enzyme-linked immunosorbent
spot (ELISpot) method on the 1st day before vaccination
and seven days (29th day) after the 2nd dose vaccine, and
both cell activities are stimulated. As with the antibody
titer in the 60 μg single-dose cohort, T cell stimulation was
also weaker, reaffirming the importance of the 2nd dose.
Cytokines were identified to evaluate the function
and polarization of RBD-specific T cells stimulated by the
vaccine encoded RBD. These cytokines are IFN gamma, IL2, and IL-4, and they are demonstrated by the intracellular
staining method in peripheral mononuclear cells collected
before and after vaccination of 52 participants immunized
with the vaccine. RBD-specific CD4 (+) T cells secrete IFN
gamma, IL-2, or both, but not IL-4. Similarly, CD8 (+) T
cells secrete IFN gamma and IL-2. The average fraction of
RBD-specific T cells obtained by BNT162b1 vaccination
in total circulating T cells was significantly higher than
that observed in 15 donors recovering from COVID-19. In
summary, these findings suggest that BNT162b1 induces
functional and proinflammatory CD4 (+) and CD8
(+) T cell responses in almost all participants with TH1
polarization [8, 9].
In December 2020, preliminary data of Phase III trials,
in which 43.448 people were randomized in the USAArgentina-Brazil-Germany-Turkey-South Africa between
July 27, 2020, and November 14, 2020, were published. In
the trial, 21,720 people were vaccinated with BNT162b2,
while 21,728 people formed the placebo arm. A total of
49% of the participants in the trial were women, 83% of
white ethnicity, 9% African American, 28% Hispanic
(Latin), 35% were obese (people with a body mass index
of at least 30), 21% had at least one concomitant medical
condition. The participants’ mean age was 52, and 42%
of them were over 55 years old. There were 8183 people
in the reactogenicity subgroup, most of them were in the
vaccine group. The most common local reaction in the
vaccine group was mild-moderate pain to the injection
site that occurred within seven days after injection. The
pain was observed less frequently in individuals over
55 years of age compared to young people. No increase
was observed in the local reaction rate after the second
injection. Local reactions have been reported as mild to
moderate reactions that resolve spontaneously within
1–2 days. Systemic reactogenicity events were observed
more frequently in young individuals aged 16–55 years
compared to individuals over 55 years of age and occurred
more frequently after the 2nd dose injections. The most
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common systemic events were weakness and headache (In
the 16–55 age group: 51%, in the >55 age group: 39%). In
the placebo group, weakness and headache were observed
at a rate of 23% and 24%, respectively, following the 2nd
injection. Fever above 38°C has been reported as 16%
in the 16–55 age group and 11% in the >55 age group.
In both the vaccine and placebo groups, the fever of 2
participants increased above 40°C. Younger participants
had a higher rate of using antipyretic and other pain
relievers compared to the elderly. The frequency of adverse
events was reported as 27% in the vaccine group and 12%
in the placebo group. Lymphadenopathy was observed
in 64 participants in the vaccine arm and 6 participants
in the placebo arm. Severe adverse events were reported
in 4 subjects in the vaccine arm, including shoulder
injury related to vaccine administration, right axillary
lymphadenopathy, paroxysmal ventricular arrhythmia,
and right leg paresthesia. Two BNT162b2 participants (1
due to atherosclerosis and the other due to cardiac arrest),
four placebo participants (2 due to unknown causes, one
hemorrhagic stroke, the other myocardial infarction) died
during the trial. None of the deaths were associated with
the vaccine or placebo, and no deaths from COVID-19
were reported7. As per the results, the vaccine’s efficacy,
administered as 30 μg in each injection with an interval
of 21 days, was reported as 95%. The vaccine’s efficacy was
similar in subgroups such as age, gender, ethnicity, and
body mass index. Of the ten severe COVID-19 infections
that occurred after the first dose of vaccination, nine
occurred in the placebo arm, while one occurred in the
vaccine arm. Nonsevere local and systemic side effects
were common in the younger age group. Besides, it was
found effective in the advanced age group, similar to those
in the younger age group [10].
As a general property of mRNA vaccines, the fact that
this vaccine has to be stored at very low temperatures
constitutes the most important logistical problem
encountered during the vaccination of large human
populations. But according to our new information, the
vaccine of Pfizer/Biontech can be stored 30 days at 2-8 0C
after taking out of deep-freeze conditions.
It has been approved by the UK, USA, Canada,
Bahrain, Saudi Arabia, and Mexico health authorities as
of December 11, 2020. As of February 8, 2021, Phase
IV trials have started. The results of Phase IV trials were
recently reported. Between February 15, 2021, and January
8, 2023, a Phase III trial is planned for pregnant women
aged 18 and over, 24-34 weeks of age 8.

2.2. Moderna
It is an mRNA vaccine surrounded by a lipid nanoparticle
(LNP). It encodes the SARS-CoV-2 spike protein. In
the Phase I trial, it was observed that the more the
dose administered to the participants, the higher the
frequency of side effects. Also, adverse events mainly
occur after the 2nd dose of the vaccine. Neutralizing
antibody and RBD-binding antibody levels were studied
in 34 healthy adults after 100 mcg vaccines administered
28 days apart. According to the follow-up results of the
volunteers participating in the Phase I trial, the presence of
neutralizing antibodies developed continues up to 90 days
after the 2nd dose of the vaccine.
No severe adverse events were observed in the vaccine
arm and the placebo arm. It was reported that the vaccine
has an inducing potential on the humoral immune response
[11]. The vaccine’s stability was determined six months at
–20 ºC, 30 days at 2–8 ºC, and 24 h at room temperature.
In the Phase III trial conducted in the USA, mRNA1273 (100 μg) was used as a placebo-controlled in
approximately 30,420 volunteers between July 27, 2020, and
October 23, 2020. While determining the vaccine’s efficacy,
it was evaluated by dividing it into subgroups such as age
(18–65 years old, >65 years old), gender, and ethnic origin.
According to the company’s results on November 16, the
vaccine’s efficacy was reported as 94.5%. All the volunteers
who participated in the trial were over 18 years old. High-risk
groups (> 65 years of age or those with underlying chronic
diseases) constituted 42% of the trial population. The Phase
III trial data, which continues with 30,420 participants in
99 centers in the USA, was published in February 2021
[12]. COVID-19 infection was detected in 2.2% of the
participants in the trial (serological/virological or both). In
the vaccine arm (mRNA-1273), the number of participants
with symptomatic COVID-19 infection was 11, compared
with 185 in the placebo group. The number of severe
COVID-19 infections was 30, all of them were in the placebo
group, and one resulted in death. Accordingly, protection
against COVID-19 disease, including severe disease, was
reported at 94.1%, and efficacy was similar in individuals
aged 65 and over. The most common adverse events were
headache, myalgia, fever, and pain at the injection site.
These adverse events occurred more frequently in both the
1st dose and the 2nd dose vaccine groups. Also, injection
site and systemic adverse events were observed more often
in the younger participant subgroup (18–65 years of age).
Less frequent adverse events were reported in individuals
who were initially COVID-19 positive 9.

7

Pfizer/Biontech Clinical Trials (2021) [online] Website https://www.pfizer.com/science/coronavirus/vaccine/rapid-progress [accessed 11 October 2020].

8

Pfizer/Biontech Clinical Trials (2021) [online] Website https://clinicaltrials.gov/ct2/show/NCT04754594 [accessed 11 October 2020].

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study (2020).
[online] Website https://investors.modernatx.com/newsreleases/news-release-details/modernas-covid-19-vaccine-candidatemeets-its-primary-efficacy
[accessed 20 November 2020].
9
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2.3. Curevac
The Phase III trial, which started on December 14, 2020
and is expected to be completed with 36,500 participants
aged 18 and over in March 2021, still continues. It is an
RNA-based vaccine that will be administered at each dose
of 12 µg with 28 days intervals 10.
2.4. Arcturus therapeutics
ARCT-021 is a vaccine containing self-replicating
(replicon) mRNA encoding the COVID-19 spike protein
in a lipid nanoparticle (LNP). The placebo-controlled,
double-blind Phase I trial in which 92 participants were
randomized was completed in January 2021. Different
doses were administered as a single injection to healthy
young adults between the ages of 21–55. The efficacy,
safety, and immunogenicity of these different doses were
evaluated. The immunological evaluation was made by
assessing the SARS-CoV-2-spike protein-specific binding
antibody and neutralizing antibody titer.
The Phase II trial, which started in January 2021
and is expected to include 600 people, is expected to be
completed in June 2022 11 . The trial consists of 4 different
groups. These groups are as follows:
I.
First dose ARCT-021 7.5 mcg-2nd dose placebo,
II. ARCT-021 7.5mcg - ARCT-021 7.5 mcg,
III. ARCT-021 5mcg - ARCT-021 5mcg,
IV. Placebo- Placebo.
While evaluating the trial’s participants, local-systemic
adverse events, adverse events requiring severe medical
assistance, new emerging chronic diseases, biochemical
and hematological changes, and SARS-CoV-2 serum
neutralizing antibody titer were considered.
2.5. GlaxoSmithKline
Phase I trial of the vaccine using self-amplifying m-RNA
in a lipid nanoparticle started as of February 17, 2021, and
10

the efficacy and safety of doses of 1 µg, 3 µg, 10 µg, 30 µg
in 40 volunteers aged 18–50 will be evaluated 12.
2.6. Imperial College London
Phase I trial is in progress 13.
2.7. Academy of Military Science (AMS)-Walvax
Biotechnology
Phase I trial is in progress 14.
2.8. Providence therapeutics
Phase I trial is in progress 15.
2.9. Chulalongkorn University
Phase I trial is in progress 16.
2.10. Moderna + National Institute of Allergy and
Infectious Diseases (NIAID)
Phase I trial is in progress 17.
2.11. Sanofi Pasteur and Translate Bio.
Phase I/II trial is in progress 18.
2.12. Daiichi Sankyo Co., Ltd.
Phase I/II trial is in progress 19.
3. Conclusion
RNA-based vaccines are safe vaccines that do not have an
infectious potential. They cause a potent immune response
by stimulating both innate immunity and adaptive
immunity with protein translation. Besides, they are stable
vaccines with fast-cheap-scalable production potential.
For these reasons, this technology is fundamental in
COVID-19 and other infectious diseases. In the following
days, we will see and use RNA-based vaccines more
effectively.
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